floxuridine + dexamethasone

Floxuridine + dexamethasone is a combination regimen primarily used as hepatic arterial infusion (HAI) therapy for the treatment of unresectable liver metastases, most commonly from colorectal cancer and other gastrointestinal malignancies. Floxuridine is an antimetabolite chemotherapeutic agent that acts as a pyrimidine analog, disrupting DNA synthesis by inhibiting thymidylate synthase after conversion to fluorouracil, thereby selectively targeting rapidly dividing tumor cells[6]. Dexamethasone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties; in this context, it is used to reduce local inflammation and biliary toxicity associated with HAI chemotherapy[5]. The combination has been studied both alone and in conjunction with systemic chemotherapy agents such as irinotecan or oxaliplatin for improved efficacy in patients with unresectable hepatic metastases[1][2][3][4][5].

Brand names

none known

Other names

FUDR + dexamethasonehepatic arterial infusion of FUDR and dexamethasone